Lorazepam/risperidone
1
Reactions 1196 - 5 Apr 2008 S Lorazepam/risperidone Respiratory insufficiency: case report A 63-year-old woman with severe emphysema developed respiratory insufficiency during treatment with lorazepam and later while receiving risperidone for anxiety. The woman, who had been receiving lorazepam [dosage not stated] for 2 days, was hospitalised with acute exacerbation of chronic obstructive pulmonary disease. The woman received bronchodilators, antibacterials and corticosteroids but, while receiving lorazepam, her pCO2 increased from a baseline level of 40mm Hg to 71mm Hg. Lorazepam was discontinued and her pCO2 subsequently improved to 56mm Hg. However, the woman’s anxiety persisted and she started receiving risperidone 0.25mg twice daily. She became increasingly hypercapnic over the following 3 days with a pCO2 increase to 77mm Hg. Risperidone was discontinued and, soon after, her pCO2 decreased to 51mm Hg. She was not receiving anxiolytic therapy on discharge, and her blood gases had normalised. Author comment: "The Naranjo ADR Probability Scale rates this event attributable to risperidone as probable (score 5–8). Not previously hypercapnic, our patient had 2 episodes of respiratory deterioration coinciding with administration of firstly lorazepam and secondly risperidone." Ricketts M, et al. Risperidone-associated respiratory depression: a case report. Canadian Journal of Hospital Pharmacy 61 (Suppl. 1): 53, Jan 2008 [Abstract] - Canada 801105301 1 Reactions 5 Apr 2008 No. 1196 0114-9954/10/1196-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Lorazepam/risperidone
Reactions 1196 - 5 Apr 2008
SLorazepam/risperidone
Respiratory insufficiency: case reportA 63-year-old woman with severe emphysema developed
respiratory insufficiency during treatment with lorazepam andlater while receiving risperidone for anxiety.
The woman, who had been receiving lorazepam [dosage notstated] for 2 days, was hospitalised with acute exacerbation ofchronic obstructive pulmonary disease.
The woman received bronchodilators, antibacterials andcorticosteroids but, while receiving lorazepam, her pCO2
increased from a baseline level of 40mm Hg to 71mm Hg.Lorazepam was discontinued and her pCO2 subsequentlyimproved to 56mm Hg.
However, the woman’s anxiety persisted and she startedreceiving risperidone 0.25mg twice daily. She becameincreasingly hypercapnic over the following 3 days with apCO2 increase to 77mm Hg. Risperidone was discontinuedand, soon after, her pCO2 decreased to 51mm Hg. She was notreceiving anxiolytic therapy on discharge, and her blood gaseshad normalised.
Author comment: "The Naranjo ADR Probability Scalerates this event attributable to risperidone as probable (score5–8). Not previously hypercapnic, our patient had 2 episodesof respiratory deterioration coinciding with administration offirstly lorazepam and secondly risperidone."Ricketts M, et al. Risperidone-associated respiratory depression: a case report.Canadian Journal of Hospital Pharmacy 61 (Suppl. 1): 53, Jan 2008 [Abstract] -Canada 801105301
1
Reactions 5 Apr 2008 No. 11960114-9954/10/1196-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
